CureVac N.V. (CVAC) Report Analysis
Corporate Events
CureVac N.V. Announces Board Changes
2022-06-22 20:05:00
CureVac N.V. at its annual general meeting held on June 22, 2022 approved appointment of Dr. Debra Barker and appointment of Dr. Klaus Schollmeier as supervisory board members and appointment of Dr. Malte Greune as managing directors.
CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.
2022-06-08 00:00:00
CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million on June 8, 2022. The total consideration for the acquisition of Frame Therapeutics will be paid in CureVac shares. CureVac N.V. (NasdaqGM:CVAC) completed the acquisition of Frame Therapeutics B.V. for €32 million on June 8, 2022.
CureVac N.V. Announces Changes of CDO
2022-06-08 00:00:00
CureVac N.V. announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila to this key role. Myriam's appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer. Myriam Mendila, MD has more than 20 years of global experience in product development, medical affairs, pharmacovigilance and healthcare compliance as well as global product strategy, including commercial strategy at Roche, Genentech and Novartis. Over the last 5 years, she has held the position of Worldwide Head of Medical Affairs and Chief Medical Officer Oncology at Novartis Pharma AG, Switzerland where she drives and oversees the development and cross-functional execution of the long-range global medical affairs vision and strategy for the Novartis oncology portfolio. Myriam earned her medical degree and subsequently doctoral degree from the Medical University of Hanover, Germany. Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology at CureVac, is responsible for defining, building and executing CureVac's oncology strategy and will serve as interim Chief Development Officer. Ulrike joined CureVac in 2011 as Head of Clinical Development and served as Chief Medical Officer from 2013-2019, before transitioning to her current role. Prior to joining CureVac, Ulrike held positions as an oncologist at theNational Center for Tumor Diseases in Heidelberg and as Global Medical Leader at Merck KGaA, where she focused on early clinical development of cancer vaccines and immune cytokines. Ulrike holds a medical degree from theUniversity of Homburg/Saar.
CureVac N.V., Annual General Meeting, Jun 22, 2022
2022-06-01 20:16:00
CureVac N.V., Annual General Meeting, Jun 22, 2022, at 14:00 Central European Standard Time. Location: Sarphatistraat 104, 1018 GV Amsterdam Netherlands Agenda: To consider adoption of the annual accounts over the financial year 2021; to consider explanation of the dividend and reservation policy; to consider release of managing directors from liability for the exercise of their duties during the financial year 2021; to consider release of supervisory directors from liability for the exercise of their duties during the financial year 2021; to consider re-appointment of Dr. Franz-Werner Haas as managing director and chair of the Management Board; to consider appointment of Dr. Malte Greune as managing director of the Management Board, COO; and to consider appointment of Dr. Klaus Schollmeier as member of the Supervisory Board; and to consider other matters.
CureVac N.V. - Shareholder/Analyst Call
2022-06-01 20:16:00
AGM
CureVac N.V. and myNEO N.V. Enters into a Research and Option Agreement
2022-05-25 20:30:00
CureVac N.V. and myNEO N.V. announced that they have entered into a research and option agreement. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. The immunogenicity of identified antigens is predicted using proprietary algorithms, machine and deep learning methods and an extensive database containing data on tumor specific mutations. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation allows for selection of antigens with the highest confidence of success for potential clinical testing.
CureVac N.V. Presents at UBS Healthcare Virtual One-on-One Day, Jun-01-2022
2022-05-20 09:24:00
CureVac N.V. Presents at UBS Healthcare Virtual One-on-One Day, Jun-01-2022 . Venue: New York, New York, United States.
UBS Investment Bank, UBS Healthcare Virtual One-on-One Day, Jun 01, 2022
2022-05-19 10:02:00
UBS Investment Bank, UBS Healthcare Virtual One-on-One Day, Jun 01, 2022. Venue: New York, New York, United States.
CureVac N.V. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 09:30 AM
2022-05-09 14:47:00
CureVac N.V. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 09:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
CureVac N.V. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022
2022-04-23 17:57:00
CureVac N.V. Presents at TIDES (Oligonucleotide & Peptide Therapeutics), May-05-2022 . Venue: Boston, Massachusetts, United States. Speakers: Benjamin Petsch, Senior Director Infectious Diseases Research.
I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022
2022-04-23 07:45:00
I.I.R Ltd., TIDES (Oligonucleotide & Peptide Therapeutics), May 05, 2022 through May 12, 2022. Venue: Boston, Massachusetts, United States.
CureVac N.V., Q4 2021 Earnings Call, Apr 28, 2022
2022-04-22 11:14:00
CureVac N.V., Q4 2021 Earnings Call, Apr 28, 2022
CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022
2022-04-22 11:14:00
CureVac N.V. announced that they will report Q4, 2021 results on Apr 28, 2022
CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK
2022-04-21 11:00:00
CureVac N.V announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed with GSK, combining two mRNAs encoding for the Beta and the Delta variant. The preclinical study, conducted in collaboration with the Friedrich-Loeffler-Institut, Germany, assessed the bivalent candidate in comparison to the corresponding monovalent candidates targeting either variant in a mouse model. Despite containing only half the dose per variant-mRNA, the combined Beta/Delta candidate elicited neutralizing antibody titers fully comparable to the monovalent candidates of the respective variant. During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals. High neutralizing antibody titers were accompanied by robust T cell responses. Notably, the bivalent Beta /Delta vaccine candidate induced two-fold higher virus neutralizing antibody titers against the Omicron variant than against the Delta variant in a rat model. This finding provides evidence for a potentially increased breadth of immune responses of the bivalent approach. The full manuscript of the preclinical data is available on the preprint server bioRxiv [1]. Within the study, transgenic mice expressing the human ACE2 receptor were immunized on day 0 and day 28 with a 0.5 µg dose of the monovalent second-generation vaccine candidate against either the ancestral virus (CV2CoV), the Beta (CV2CoV.351) or the Delta (CV2CoV.617.2) variant, or with a 0.5 µg dose of the bivalent vaccine candidate combining the Beta and Delta variant (CV2CoV.351+ CV2CoV.617.2). Vaccinated animals were challenged on day 56 with either the Beta or the Delta virus variant. Vaccine induced T cells, including lung-resident memory CD8+ T cells, were characterized by flow cytometry. Additionally, the neutralizing capacity of the mono- and bivalent candidates was tested against multiple virus variants, including Omicron in serum samples of immunized Wistar rats.
CureVac N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:30 AM
2022-04-13 11:14:00
CureVac N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 09:30 AM. Venue: Marriott Marquis, New York City, New York, United States.
CureVac N.V. and GSK Enters into Contract with German Federal Government to Supply Mrna Vaccines
2022-04-11 20:16:00
On April 11, 2022, CureVac N.V. announced that they and GSK have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government access to CureVac’s manufacturing capacity until 2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the pandemic or in future infectious disease outbreaks.
Curevac and GSK Enter into Pandemic Preparedness Contract with German Government
2022-04-11 11:00:00
CureVac N.V. and GSK announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government access to CureVac's manufacturing capacity until 2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the current pandemic or in future infectious disease outbreaks. By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation. Under the contract, the federal government will pay CureVac and GSK an annual standby fee after successful completion of the setup period, which requires the companies to maintain manufacturing capacity at constant readiness. By ensuring the availability of manufacturing capacities in Germany, the arrangement will significantly contribute to strengthening pandemic preparedness.
CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV
2022-03-30 20:31:00
CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens. A preclinical study of CV2CoV in cynomolgus macaques, published in Nature in November 2021, demonstrated rapid induction of higher antibody titers, better induction of immune memory and stronger protective efficacy of CV2CoV compared to CureVac’s first-generation vaccine candidate, CVnCoV. The same study demonstrated comparable neutralizing antibody titers in animals fully vaccinated with either 12µg of CV2CoV or a 30µg standard dose of a licensed mRNA COVID-19 vaccine. The Phase 1 dose-escalation study is being conducted at clinical sites in the U.S. and is expected to enroll up to 210 healthy adults to evaluate the safety, reactogenicity and immunogenicity of CV2CoV in the dose range of 2 to 20µg. Data results from the Phase 1 study are expected in the second half of 2022. The program follows the recent start of the Phase 1 clinical study for the jointly developed seasonal influenza vaccine candidate, CVSQIV, also applying the optimized second-generation mRNA backbone. The CureVac-GSK infectious disease collaboration was first announced in July 2020 and focuses on the development of new products based on CureVac’s mRNA technology for different targets in the field of infectious diseases. In 2022, both companies have broadened their development strategy to test chemically modified mRNA technologies in addition to unmodified mRNA. Clinical programs with chemically modified mRNA for COVID-19 and influenza are expected to start later this year.
CureVac N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022
2022-03-29 06:52:00
CureVac N.V. Presents at 14th Kempen Life Sciences Conference, Apr-20-2022 . Venue: Amsterdam, Netherlands.
CureVac N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08:00 AM
2022-03-11 14:00:00
CureVac N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08:00 AM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Pierre Kemula, MD, CFO & Member of Management Board.
CureVac N.V. Presents at UBS Global Healthcare Conference, May-24-2022
2022-03-11 07:21:00
CureVac N.V. Presents at UBS Global Healthcare Conference, May-24-2022 . Venue: Lotte New York Palace, New York City, New York, United States.
CureVac N.V. Presents at Eighth Annual Berenberg Conference USA 2022, May-23-2022 03:30 PM
2022-03-11 07:21:00
CureVac N.V. Presents at Eighth Annual Berenberg Conference USA 2022, May-23-2022 03:30 PM. Venue: Tarrytown House Estate, 49 East Sunnyside Lane, Tarrytown, New York, New York, United States. Speakers: Franz-Werner Haas, CEO & Member of Management Board.
UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022
2022-03-03 04:07:00
UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022. Venue: Lotte New York Palace, New York City, New York, United States.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022
2022-02-16 16:45:00
JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
2022-02-10 12:00:00
CureVac N.V. announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK. The differentiated multivalent vaccine candidate features multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. The use of customizable and rapidly produced mRNAs to address influenza could enable faster development and delivery of potentially improved vaccine candidates, featuring even short-term strain updates for the approaching influenza season. The Phase 1 dose-escalation study is being conducted in Panama and is expected to enroll up to 240 healthy adult participants to evaluate the safety, reactogenicity and immunogenicity of CVSQIV. In line with the mRNA development strategy in collaboration with GSK, both companies are also working on chemically modified mRNA technologies with clinical programs for influenza and COVID-19 expected to start later this year. The CureVac-GSK infectious disease collaboration was first announced in July 2020 and focuses on the development of new products based on CureVac's mRNA technology for different targets in the field of infectious diseases.
Joh. Berenberg, Gossler & Co. KG, Eighth Annual Berenberg Conference USA 2022, May 23, 2022 through May 25, 2022
2021-12-21 05:07:00
Joh. Berenberg, Gossler & Co. KG, Eighth Annual Berenberg Conference USA 2022, May 23, 2022 through May 25, 2022. Venue: Tarrytown House Estate, 49 East Sunnyside Lane, Tarrytown, New York, New York, United States. The conference will bring together companies to present their corporate strategy, current trends and challenges. Running in parallel with the main presentations, companies will be hosting small group and one-on-one meetings.
CureVac N.V.(NasdaqGM:CVAC) added to NASDAQ Biotechnology Index
2021-12-20 00:00:00
CureVac N.V. has been added to NASDAQ Biotechnology Index.
CureVac N.V., Q3 2021 Earnings Call, Nov 19, 2021
2021-11-18 21:14:00
CureVac N.V., Q3 2021 Earnings Call, Nov 19, 2021
CureVac N.V. Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
2021-11-18 10:42:00
CureVac N.V. announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature. The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12-g of CV2CoV or a 30-g standard dose of Comirnaty(R) were shown to be highly comparable. The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model, providing substantiated support for the unmodified mRNA technology approach. This applies not only to the development of COVID-19 vaccines but to the mRNA technology field as a whole. The study, conducted in collaboration with Dan Barouch, MD, PhD, of Beth Israel Deaconess Medical Center, investigated immune responses as well as the protective efficacy of CV2CoV and first-generation candidate, CVnCoV, against SARS-CoV-2 challenge in cynomolgus macaques. It was made available via the bioRxiv preprint server in August 2021. For additional details, please refer to the previously issued press release. About the Study: Within the study, CV2CoV and CVnCoV were tested in cynomolgus macaques immunized with a 12-g dose of the respective candidate on day 0 and day 28. For comparison with Comirnaty(R), animals were vaccinated twice, on day 0 and day 21, with 30-g of the licensed vaccine and antibody titers were measured at peak immunity at week 5. Within the comparison of CV2CoV with CVnCoV, CV2CoV consistently showed better activation of innate and adaptive immune responses, resulting in earlier response onset, higher antibody titers and stronger memory B and T cell activation. Higher antibody neutralizing capacity was observed with CV2CoV across a range of relevant variants, including the Delta variant. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected than animals vaccinated with CVnCoV based on effective clearance of the virus in the lungs and nasal passages.
Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022
2021-11-13 00:00:00
Kempen & Co, 14th Kempen Life Sciences Conference, Apr 20, 2022 through Apr 21, 2022. Venue: Amsterdam, Netherlands.
CureVac N.V. Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
2021-11-10 12:00:00
CureVac N.V. announced promising data from the completed dose-escalation part of the Phase 1 clinical trial of CV8102, the company's lead oncology candidate. The data support the hypothesis that local injection of the RNA immuno-modulator into a single tumor lesion is able to induce a systemic response leading to immune attack against both injected and non-injected tumors. Extensive analysis of immune cell activation shows efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma signaling pathways. Serial tumor biopsies from individual patients demonstrated increased infiltration of tumor-fighting T cells in the microenvironment of injected as well as non-injected tumors. The study focuses on patients with advanced cutaneous melanoma, adenoid cystic carcinoma and squamous cell carcinoma of the skin or head and neck, treated with CV8102 alone and in combination with anti-PD-1 antibodies. The data are being presented at the Society for Immunotherapy of Cancer (SITC) Conference, held in Washington, D.C., and virtually from November 10-14, 2021. An expansion part of the Phase 1 study, initiated in February and fully recruited in October 2021, aims to confirm the safety, tolerability and efficacy of CV8102 at the recommended 600µg dose in patients with advanced melanoma. The study involves 40 trial participants, with 10 in the single-agent cohort and 30 in the combination cohort. Data from the expansion part of the study is expected in the second half of 2022. The dose-escalation part of the study included a total of 58 patients, 33 of which were treated in the in the single-agent cohort and 25 in the combination cohort. Data presented in September at the European Society for Medical Oncology (ESMO) conference found that as of the cutoff date of June 21, 2021, in the single-agent CV8102 dose-escalation cohort, one patient with a complete response and two patients with a partial response were observed. In addition, 12 patients experienced stable disease. In the PD-1 combination dose-escalation cohort, one PD-1 refractory melanoma patient experienced a partial response while three patients experienced stable disease.
CureVac N.V. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021
2021-11-07 10:00:00
CureVac N.V. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-08-2021 . Venue: Rancho Palos Verdes, California, United States.
JMP Securities LLC, JMP Securities Hematology & Oncology Summit, Dec 06, 2021 through Dec 07, 2021
2021-10-29 18:02:00
JMP Securities LLC, JMP Securities Hematology & Oncology Summit, Dec 06, 2021 through Dec 07, 2021.
CureVac N.V. Presents at JMP Securities Hematology & Oncology Summit, Dec-07-2021 01:00 PM
2021-10-29 18:02:00
CureVac N.V. Presents at JMP Securities Hematology & Oncology Summit, Dec-07-2021 01:00 PM. Speakers: Pierre Kemula, MD, CFO & Member of Management Board, Sarah Fakih, Vice President Corporate Communications & Investor Relations, Ulrike Gnad-Vogt.
SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022
2021-10-29 14:57:00
SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.
CureVac N.V. Presents at Berenberg European Conference, Dec-08-2021
2021-10-22 02:59:00
CureVac N.V. Presents at Berenberg European Conference, Dec-08-2021 . Venue: Pennyhill Park Hotel & Spa, London Road, Bagshot, Surrey, United Kingdom. Speakers: Pierre Kemula, MD, CFO & Member of Management Board, Sarah Fakih, Vice President Corporate Communications & Investor Relations.
Interplan AG, 9th International mRNA Health Conference, Nov 09, 2021 through Nov 10, 2021
2021-10-13 17:05:00
Interplan AG, 9th International mRNA Health Conference, Nov 09, 2021 through Nov 10, 2021.
Interplan AG, 9th International mRNA Health Conference, Nov 09, 2021 through Nov 10, 2021
2021-10-13 17:05:00
Interplan AG, 9th International mRNA Health Conference, Nov 09, 2021 through Nov 10, 2021.
CureVac N.V. Presents at 9th International mRNA Health Conference, Nov-09-2021 through Nov-10-2021
2021-10-13 17:05:00
CureVac N.V. Presents at 9th International mRNA Health Conference, Nov-09-2021 through Nov-10-2021. Presentation Date & Speakers: Nov-09-2021, Franz-Werner Haas, CEO & Member of Management Board, Igor Splawski, Chief Scientific Officer & Member of Management Board, Patrick Baumhof, Senior Vice President Formulation & Delivery, Susanne Rauch, Associate Director Infectious Diseases Research. Nov-10-2021, Igor Splawski, Chief Scientific Officer & Member of Management Board, Patrick Baumhof, Senior Vice President Formulation & Delivery.
Informa plc, TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov 15, 2021 through Nov 17, 2021
2021-10-12 20:23:00
Informa plc, TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov 15, 2021 through Nov 17, 2021.
CureVac N.V. Presents at TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov-15-2021 through Nov-17-2021
2021-10-12 20:23:00
CureVac N.V. Presents at TIDES EUROPE: Oligonucleotide & Peptide Therapeutics, Nov-15-2021 through Nov-17-2021. Presentation Date & Speakers: Nov-16-2021, Nicole Roth, Senior Scientist.
CureVac N.V. - Special Call
2021-10-12 13:00:00
To discuss Focus Shift to Second-Generation mRNA Technology
CureVac N.V. - Special Call
2021-10-12 13:00:00
CureVac N.V. - Special Call
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
2021-10-12 11:02:00
CureVac N.V. announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA). In view of a recent EMA communication, CureVac estimates that the earliest potential approval of CVnCoV would come in the second quarter of 2022. By this time, the companies expect the candidates from the second-generation vaccine program to have progressed to late-stage clinical development. The decision is also aligned with the evolving dynamics of the pandemic response towards a greater need for differentiated vaccines to address the developing endemic SARS-CoV2 situation. As a direct consequence, the existing Advanced Purchase Agreement with the European Commission, which was predicated on employing CVnCoV to address the acute pandemic need, will cease. CureVac is assessing the possibility of leveraging CVnCoV commitments for the second-generation vaccine candidates. CureVac remains in contact with the European Commission and is supportive of its public health efforts.
CureVac N.V. Presents at Berenberg US CEO Conference 2021, Nov-09-2021
2021-09-30 18:42:00
CureVac N.V. Presents at Berenberg US CEO Conference 2021, Nov-09-2021 .
CureVac N.V. has filed a Shelf Registration.
2021-09-17 00:00:00
CureVac N.V. has filed a Shelf Registration. Security Name: Common Shares Security Name: Debt Securities Security Name: Warrants Security Name: Subscription Rights Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration
CureVac N.V. has filed a Follow-on Equity Offering in the amount of $600 million.
2021-09-17 00:00:00
CureVac N.V. has filed a Follow-on Equity Offering in the amount of $600 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,084,027 Price\Range: $66.05 Transaction Features: At the Market Offering
CureVac Streamlines European Network for mRNA Product Manufacturing
2021-09-14 11:19:00
CureVac N.V. announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines following the first wave of the pandemic vaccination efforts and corresponding changes in the demand of its first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with the European Medicines Agency (EMA). As a result, the existing contracts with WACKER for the manufacturing of the mRNA drug substance of CVnCoV and Celonic for the manufacturing and formulation of the mRNA drug substance of CVnCoV will be terminated. CureVac's existing agreements with Rentschler Biopharma and Novartis for mRNA production and formulation are unaffected by this adjustment and remain in place. Streamlining of capacity does not limit availability of clinical trial material for CV2CoV, the second-generation COVID-19 vaccine candidate jointly developed with GSK, expected to enter the clinic in the fourth quarter of 2021.
Joh. Berenberg, Gossler & Co. KG, Berenberg US CEO Conference 2021, Nov 09, 2021 through Nov 10, 2021
2021-09-07 11:00:00
Joh. Berenberg, Gossler & Co. KG, Berenberg US CEO Conference 2021, Nov 09, 2021 through Nov 10, 2021.
CureVac N.V.'s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
2021-08-31 11:00:00
CureVac N.V. announced the publication of its pivotal Phase 2b/3 (HERALD study) primary data of CVnCoV, its first-generation COVID-19 vaccine candidate, in Preprints with The Lancet. The HERALD study enrolled approximately 40,000 participants in ten countries across Latin America and Europe, in the predefined age groups 18 to 60 and above 60. For the final analysis, COVID-19 cases were caused by 15 different virus variants. As previously announced, the data were based on 228 adjudicated COVID-19 cases, occurring at least two weeks after administration of the second dose. CVnCoV demonstrated overall vaccine efficacy of 48% against COVID-19 disease of any severity, including single non-respiratory mild symptoms. Significant protection was demonstrated among participants in the age group of 18 to 60, with an efficacy of 53% against disease of any severity and across all 15 identified strains; protection against moderate to severe disease for this age group was calculated to be 77%. In the same age group, CVnCoV provided 100% protection against hospitalization or death. CureVac is in close interaction with the European Medicines Agency (EMA) and will continue to seek regulatory approval for CVnCoV to leverage the vaccine's strengths in the large segment of the population where it provides demonstrated protection. Submission of comprehensive clinical data packages to the EMA is ongoing as part of the rolling submission initiated in February 2021 and is expected to be finalized toward the end of the third quarter of 2021. As the lack of effective vaccines is still a challenge in many parts of the world, CVnCoV has the potential to contribute to the fight against COVID-19 and the increasingly complex variant context, which warrants a vaccine that has been clinically tested in a variant-dominated environment.
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
2021-08-30 11:00:00
CureVac N.V. announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology. The study was conducted in collaboration with experts of the highly renowned REBIRTH-Research Center for Translational Regenerative Medicine and Department of Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, Hannover (Germany), which allowed access to well-established preclinical liver disease models. It provides the first preclinical data demonstrating the therapeutic applicability of mRNA-encoded HNF4A (hepatocyte nuclear factor 4 alpha) transcription factor in the treatment of liver fibrosis and cirrhosis. Liver fibrosis is characterized by the formation of scar tissue in the liver, causing gradual impairment of liver function. This process can evolve into irreversible and advanced stage cirrhosis, resulting in liver failure or cancer. HNF4 alpha is an important regulator and key factor in liver metabolism, which has been shown to gradually decrease with disease progression. In this study, four independent mouse models of the disease were treated with mRNA encoding HNF4A. The treatment was able to restore HNF4A levels and thereby significantly reduced liver injury. Within the study, lipid nanoparticles formulated to contain human HNF4A mRNA were injected repeatedly via intravenous administration in four independent mouse models of the disease. Eight repeated injections of 1 and 2 mg/kg of formulated mRNA demonstrated the ability to significantly reduce liver fibrosis/injury and restore cellular processes necessary to recover normal liver function. Future research will focus on optimizing the mRNA for further non-clinical and clinical development.
CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
2021-08-16 11:19:00
CureVac N.V. announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates. The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. Higher antibody neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. The full manuscript of the preclinical data is available on the preprint server bioRxiv. Within the study, CVnCoV and CV2CoV were tested in cynomolgus macaques immunized with a 12µg dose of the respective candidate on day 0 and day 28. Induction of innate immunity was investigated via specific cytokine markers. Adaptive immune responses were assessed based on receptor binding domain specific antibodies and neutralizing antibodies as well as memory B and T cells. Impact of Variants of Concern and Variants of Interest on neutralizing antibody titers was tested against the Alpha, Beta, Delta, Kappa and the Lambda variant. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus. The CureVac-GSK COVID-19 collaboration announced in February 2021 extends the existing strategic mRNA technology partnership both companies started in July 2020, which focuses on the development of new products based on CureVac’s second-generation mRNA-technology for different targets in the field of infectious diseases. The optimized mRNA backbone that is being used in this collaboration also has the potential for a multivalent or combination approach to address multiple emerging variants in one vaccine. Following the current preclinical development of CV2CoV, a Phase 1 clinical trial is expected to start in Fourth Quarter 2021.
CureVac N.V. to Report Q2, 2021 Results on Aug 16, 2021
2021-08-16 00:00:00
CureVac N.V. announced that they will report Q2, 2021 results on Aug 16, 2021
CureVac N.V. Presents at Berenberg & Goldman Sachs 10th German Corporate Conference, Sep-20-2021
2021-07-26 17:42:00
CureVac N.V. Presents at Berenberg & Goldman Sachs 10th German Corporate Conference, Sep-20-2021 .
Joh. Berenberg, Gossler & Co. KG, Berenberg European Conference, Dec 06, 2021 through Dec 10, 2021
2021-07-09 09:03:00
Joh. Berenberg, Gossler & Co. KG, Berenberg European Conference, Dec 06, 2021 through Dec 10, 2021. Venue: Pennyhill Park Hotel & Spa, London Road, Bagshot, Surrey, United Kingdom.
CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV
2021-06-30 20:35:00
CureVac N.V. announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV. In the unprecedented context of 15 strains circulating within the study population at the time of final analysis, CVnCoV demonstrated an overall vaccine efficacy of 48% (vaccine 83 vs. 145 placebo) against COVID-19 disease of any severity, including single non-respiratory mild symptoms. Significant protection was demonstrated among participants in the age group of 18 to 60, with an efficacy of 53% (vaccine 71 vs. 136 placebo) against disease of any severity and across all 15 identified strains; protection against moderate to severe disease was calculated to be 77% (9 vaccine vs. 36 placebo). In the same age group, CVnCoV provided 100% protection (vaccine 0 vs. 6 placebo) against hospitalization or death. In participants above 60 years, who represented 9% of the analysed cases, the available data did not enable a statistically significant determination of efficacy. The data confirm the favorable safety profile of CVnCoV in all age groups. The study will continue to complete follow-up analyses for trial participants. Available data have been communicated to the European Medicines Agency (EMA). In total, 228 adjudicated COVID-19 cases (83 vaccine vs. 145 placebo) were assessed in the final analysis. In the age group of 18 to 60, across strains of higher prevalence, strain-dependent vaccine efficacy ranged from approximately 42% to up to 67%. Out of the 228 cases, 204 were sequenced to identify the variant causing the infection. Approximately 86% of these cases were caused by Variants of Concern (~51%) and Variants of Interest (~35%), the latter including the Lambda strain, first identified in Peru (~21%) and B.1.621, first identified in Colombia (~14%). Approximately 3% of cases were attributable to the original SARS-CoV-2 virus. The remaining 11% were caused by less-explored strains. The HERALD study, enrolled approximately 40,000 participants in ten countries in Latin America and Europe. Statistical success criteria for the final analysis were met on the basis of 228 cases, occurring at least two weeks after administration of the second dose, including 68 additional adjudicated cases compared to the pre-defined 160 cases as per trial protocol. To identify COVID-19 strains within the trial, sequencing of virus variants has been performed on 588 COVID-19 cases, of which 204 fulfilled adjudication criteria and were included in the efficacy analysis. Beyond CVnCoV, the company is developing second-generation COVID-19 vaccine candidates in partnership with GSK. These candidates are based on new mRNA backbones and include potential variants in multivalent vaccine formats as well as combination vaccines for potential protection against multiple infectious diseases in single injection. Preclinical data from the first vaccine candidate, CV2CoV, has recently been published in Nature Communications. CureVac and GSK expect to progress the second-generation vaccine candidate into clinical testing in the third quarter of 2021, with the goal of introducing the vaccine in 2022, subject to regulatory approval.
CureVac N.V. - Special Call
2021-06-30 20:30:00
To discuss results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV
CureVac N.V. - Special Call
2021-06-30 20:30:00
To discuss results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV
CureVac N.V. Announces Executive Changes
2021-06-30 12:10:00
CureVac N.V. announced the appointment of Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021. In this position, he will strengthen the company's Management Board and will head, among others, CureVac's clinical and commercial manufacturing activities. Dr. Greune joins CureVac with extensive experience in the global pharmaceutical industry, including manufacturing of vaccines and fill & finish of biologics. CureVac also announced that Dr. Florian von der Mülbe, co-founder and Chief Production Officer, will now focus his extensive production expertise exclusively on the expansion and accelerated development of The RNA Printer(R), CureVac's solution for mobile, autonomous and fully automated manufacturing of GMP-grade RNA vaccines and therapeutics. To drive this key strategic project forward, which requires building its own operational infrastructure, Dr. von der Mülbe will resign from the Management Board of CureVac N.V. Dr. Greune will assume Dr. von der Mülbe's position on the Management Board. Dr. Greune joins CureVac from Sanofi-Aventis Deutschland GmbH where he held various management positions for almost ten years. As General Manager and Vice President Cartridges, Devices & Insulin Technology Group he was responsible for several manufacturing sites in Frankfurt.
Fundamental Summary
Looking at CureVac's financials of Q1 reflected decent results. We do believe, though, that macro-related market conditions will influence their performance more significantly than its individual results. Bottom line, CureVac's financials indicate solid performance in terms of growth and income, which leads us to believe that they may become interesting again in the next few months. But for right now, we gave the company an overall grade of 70 and a HOLD recommendation.
CureVac reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was EUR 24.37 million compared to EUR 10.03 million a year ago. Net loss was EUR 15.09 million compared to EUR 113.7 million a year ago. Basic loss per share from continuing operations was EUR 0.08 compared to EUR 0.62 a year ago.
Business Description
CureVac, a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Sector Overview
CureVac is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. CureVac's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -45.2 | 23.2% | 71 | |
| Net Cashflow | -838.7 | -64.1% | 87 | |
| Capital Expenditure | -106.2 | 14.5% | 90 | |
| Asset Turnover | 0.1 | 0.0% | 70 | |
| Free Cashflow | -4.2 | 9.6% | 80 |
* All values are TTM
The below chart reflects CureVac's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While CureVac's peer average final assessment score stands on 65.0, CureVac's score is 70.
- CVAC
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. CureVac's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), CureVac's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.
5D MA
14.38
50D MA
16.33
200D MA
28.02
MACD
-0.84
RSI
19.98
STOCH
23.03
Balance Sheet Analysis
A few key balance sheet metrics in this report were discouraging. CureVac's liabilities stood at 351.8 in the current filing, which represents a -25.1% change from the previous report. These liabilities metrics show that management has been unsuccessful in encouraging healthy growth while managing liabilities. Therefore, we rated their liabilities movement with a score of 49. Also, CureVac's price to book ratio (P/B) was reported as 4.3 and represents -47.8% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. Their book value factor metrics are even more concerning when compared to their peers. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 52. However, we can draw some encouragement from CureVac's momentum in Equity generation. CureVac did a great job related to equity this period, which stood at 674.9, representing a -2.0% change. Companies in the same sector and market capitalization will usually be affected by up to 7.3 percent by this parameter. These equity changes appear exceptionally balanced and impressive objectively compared to their peers. Therefore, its equity movement component earned a score of 75. The company's balance sheet, Therefore, earned a score of 57.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 1,026.7 | -11.4% | 64 |
| Liabilities | 351.8 | -25.1% | 49 |
| Price to Book | 4.3 | -47.8% | 52 |
| Cash & Equivalents | 658.2 | -18.9% | 52 |
| Equity | 674.9 | -2.0% | 75 |
The below chart describes CureVac's performance as reflected on its balance sheet with respect to its peers. While CureVac received a balance sheet score of 57, the average of its peers stands on 61.0.
- CVAC
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 0 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 1 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 2 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 3 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 4 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 9 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 10 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 11 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 16 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 18 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 22 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 26 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 27 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 28 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 30 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 40 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 42 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 44 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 47 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 57 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 73 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 74 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 75 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 94 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
CureVac appears likely to maintain its strong income statement metrics and momentum going forward. CureVac's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -950.0, which represents a 8.6% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Consequently, their EBITDA movement received a grade of 83. Also, In this filing, CureVac reported a return on equity (ROE) ratio of -45.2, which represents a change of 23.2%. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Therefore, its return factors component earned a score of 71. On the other hand, Revenue Efficiency, jumped out as looking rather underwhelming. CureVac management did an underwhelming job managing revenue efficiency this past period. CureVac's revenue efficiency is 117.3 according to the metrics in the current filing, which represents a 13.9% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. As a result, their revenue efficiency earned a score of 45. Therefore, we scored its income statement a 74.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -950.0 | 8.6% | 83 |
| Total Revenues | 117.3 | 13.9% | 45 |
| Return on Equity | -45.2 | 23.2% | 71 |
The below chart describes CureVac's performance as reflected on its income statement with respect to its peers. While CureVac received a income statement score of 74 , the average of its peers stands on 62.0.
- CVAC
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 0 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 1 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 2 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 3 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 4 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 9 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 10 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 11 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 16 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 18 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 22 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 26 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 27 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 28 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 30 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 40 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 42 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 47 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 73 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 74 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 94 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Capex and Net Cash Flow stand out as the most significant drivers of CureVac's cash flow's strength. CureVac's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. CureVac recorded CapEx of -106.2, which represents 14.5% change from the previous report. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 90. Also, CureVac's management was effective in improving their net cash flow, which now sits at -838.7 and represents a -64.1% change from the previous report. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 87. That said, one metric, Asset Turnover, stood out as strongly negative. Asset turnover metrics during this period were surprisingly weak. Their reported asset turnover metrics of 0.1, which represents a 0.0% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Underwhelming results in asset turnover metrics often lead to negative pressure in stock prices, so we rated its asset turnover momentum 70. Consequently, its cash flow earned a score of 90.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -838.7 | -64.1% | 87 |
| Capital Expenditure | -106.2 | 14.5% | 90 |
| Asset Turnover | 0.1 | 0.0% | 70 |
| Free Cashflow | -4.2 | 9.6% | 80 |
The below chart describes CureVac's performance as reflected on its cash flow with respect to its peers. While CureVac received a cash flow score of 90, the average of its peers stands on 75.0.
- CVAC
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 0 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 1 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 2 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 3 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 4 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 5 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 6 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 7 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 8 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 9 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 10 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 11 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 12 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 13 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 14 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 15 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 16 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 17 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 18 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 19 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 20 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 21 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 22 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 23 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 24 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 25 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 26 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 27 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 28 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 29 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 30 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 31 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 32 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 33 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 34 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 35 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 36 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 37 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 38 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 39 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 40 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 41 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 42 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 43 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 44 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 45 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 46 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 47 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 48 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 49 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 50 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 51 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 54 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 55 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 56 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 57 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 58 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 59 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 60 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 61 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 62 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 63 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 64 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 65 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 66 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 67 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 68 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 69 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 70 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 73 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 74 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 75 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 76 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 77 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 80 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 81 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 82 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 83 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 84 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 85 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 86 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 92 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 93 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 94 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 95 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.